Condition: Carcinoma, Non-Small-Cell Lung · Sponsor: Merck Sharp & Dohme LLC
The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) with or without chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, MK-0482, I-DXd, or HER3-DXd in treatment-naïve participants with advanced squamous or non-squamous NSCLC. This study is one of the pembrolizumab substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01).
This description comes directly from the study's public registry record.
Toll Free Number · 1-888-577-8839 · Trialsites@msd.com
Always discuss trial participation with your own doctor first.
| Banner MD Anderson Cancer Center ( Site 0001) | Gilbert, Arizona, United States | Active Not Recruiting |
| City of Hope ( Site 0014) | Duarte, California, United States | Completed |
| UCSF Medical Center at Mission Bay ( Site 0007) | San Francisco, California, United States | Completed |
| Georgetown University ( Site 0036) | Washington D.C., District of Columbia, United States | Completed |
| University of Kentucky Markey Cancer Center ( Site 0019) | Lexington, Kentucky, United States | Completed |
| MedStar Franklin Square Medical Center ( Site 0033) | Baltimore, Maryland, United States | Completed |
| Massachusetts General Hospital ( Site 0003) | Boston, Massachusetts, United States | Completed |
| Dana Farber Cancer Institute ( Site 0002) | Boston, Massachusetts, United States | Completed |
| Oncology Hematology West, PC DBA Nebraska Cancer Specialists ( Site 0031) | Omaha, Nebraska, United States | Completed |
| Dartmouth Hitchcock Medical Center ( Site 0016) | Lebanon, New Hampshire, United States | Recruiting |
| John Theurer Cancer Center at Hackensack University Medical Center ( Site 0037) | Hackensack, New Jersey, United States | Completed |
| Laura and Isaac Perlmutter Cancer Center ( Site 0034) | New York, New York, United States | Completed |
+ 34 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04165070